Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
This is a single-center, single-arm, phase II clinical study, to explore the efficacy and safety of modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar as first line treatment in patients with advanced hepatocellular carcinoma.
- EligibilityCriteria: Inclusion Criteria:  Be willing and able to provide written informed consent/assent for the trial. Males or unpregnant females who age ≥ 18 years, ≤75 years. The investigator believes the patient is capable of complying with the study protocol. Histologically, cytologically or clinically confirmed advanced hepatocellular carcinoma. is not a candidate for radical surgery not received previous systemic treatment patients must have at least one measurable lesion (RECIST 1.1) ECOG PS：0-1, 14 days before enrollment Child-Pugh A or Child-Pugh B ≤ 7, 14 days before enrollment  Exclusion Criteria:  Prior history of other malignant tumors Current or prior immunodeficiency disorders or autoimmune diseases Subjects have untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk of bleeding Subjects who are not available for follow-up or are participating in other clinical trials that have the potential to interfere with this study Conditions considered unsuitable for inclusion by researchers - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult